Cowa LLC Purchases New Shares in Johnson & Johnson $JNJ

Cowa LLC purchased a new stake in Johnson & Johnson (NYSE:JNJ) in the 4th quarter, HoldingsChannel.com reports. The fund purchased 2,154 shares of the company’s stock, valued at approximately $446,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Sumitomo Mitsui Financial Group Inc. raised its position in Johnson & Johnson by 38.4% in the 4th quarter. Sumitomo Mitsui Financial Group Inc. now owns 1,543 shares of the company’s stock valued at $320,000 after purchasing an additional 428 shares during the last quarter. First Financial Bankshares Inc raised its position in Johnson & Johnson by 2.2% in the 4th quarter. First Financial Bankshares Inc now owns 709,380 shares of the company’s stock valued at $146,806,000 after purchasing an additional 15,514 shares during the last quarter. Nuveen LLC raised its position in Johnson & Johnson by 6.9% in the 4th quarter. Nuveen LLC now owns 10,609,171 shares of the company’s stock valued at $2,195,568,000 after purchasing an additional 683,967 shares during the last quarter. Xponance LLC raised its position in Johnson & Johnson by 5.0% in the 4th quarter. Xponance LLC now owns 410,272 shares of the company’s stock valued at $84,906,000 after purchasing an additional 19,527 shares during the last quarter. Finally, Advisory Resource Group purchased a new stake in Johnson & Johnson in the 4th quarter valued at $225,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson reported strong Phase 2/3 results for IMAAVY (nipocalimab-aahu) in warm autoimmune hemolytic anemia, showing a statistically significant durable hemoglobin response and rapid onset of effect in a disease with no FDA-approved therapies. That strengthens the company’s rare-disease pipeline and could create a new growth driver. Article Title
• Positive Sentiment: The company is expanding U.S. availability of TECNIS PureSee IOL, a cataract surgery lens, which adds another incremental commercial win in medtech and supports recurring product revenue. Article Title
• Positive Sentiment: Johnson & Johnson will acquire Firefly Bio for about $1 billion, a move aimed at strengthening its oncology pipeline and signaling continued investment in high-growth cancer treatments. Article Title
• Positive Sentiment: Several recent pieces highlight bullish valuation and dividend arguments, with investors pointing to JNJ’s strong balance sheet, durable cash flow, and attractive long-term total returns. Analysts also lifted some earnings estimates, reinforcing the view that the stock remains a defensive compounder. Article Title
• Neutral Sentiment: Recent commentary from Jim Cramer and other market writers praised Johnson & Johnson’s “great new drug profits” and “AAA balance sheet,” which may have helped sentiment but did not include a major new fundamental update. Article Title
• Negative Sentiment: The main offsetting headline is a $32 million asbestos/talc verdict in Los Angeles, which keeps legal risk in focus and could pressure sentiment around the stock’s litigation overhang. Article Title

Johnson & Johnson Stock Up 0.0%

Shares of Johnson & Johnson stock opened at $238.59 on Friday. The firm has a fifty day moving average of $231.58 and a two-hundred day moving average of $227.11. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.77 and a current ratio of 1.03. The company has a market cap of $574.33 billion, a P/E ratio of 27.58, a PEG ratio of 2.34 and a beta of 0.26. Johnson & Johnson has a one year low of $149.04 and a one year high of $251.71.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, April 14th. The company reported $2.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.68 by $0.02. The business had revenue of $24.06 billion during the quarter, compared to the consensus estimate of $23.60 billion. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. The business’s revenue was up 9.9% compared to the same quarter last year. During the same quarter last year, the firm posted $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. On average, analysts forecast that Johnson & Johnson will post 11.57 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 9th. Stockholders of record on Tuesday, May 26th were issued a $1.34 dividend. The ex-dividend date was Tuesday, May 26th. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.2%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.30. Johnson & Johnson’s payout ratio is 61.97%.

Wall Street Analyst Weigh In

A number of brokerages have commented on JNJ. Citigroup upped their price objective on shares of Johnson & Johnson from $274.00 to $285.00 and gave the stock a “buy” rating in a research report on Tuesday, April 7th. Johnson Rice upgraded shares of Johnson & Johnson from a “hold” rating to an “outperform” rating in a research report on Wednesday, May 13th. Wells Fargo & Company upped their price objective on shares of Johnson & Johnson from $240.00 to $263.00 and gave the stock an “overweight” rating in a research report on Wednesday, April 15th. JPMorgan Chase & Co. upped their price objective on shares of Johnson & Johnson from $250.00 to $260.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 15th. Finally, Royal Bank Of Canada restated an “outperform” rating and set a $265.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, April 15th. Twenty research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $253.04.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.